IL248095A0 - Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir - Google Patents
Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavirInfo
- Publication number
- IL248095A0 IL248095A0 IL248095A IL24809516A IL248095A0 IL 248095 A0 IL248095 A0 IL 248095A0 IL 248095 A IL248095 A IL 248095A IL 24809516 A IL24809516 A IL 24809516A IL 248095 A0 IL248095 A0 IL 248095A0
- Authority
- IL
- Israel
- Prior art keywords
- darunavir
- emtricitabine
- tenofovir
- ritonavir
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461976917P | 2014-04-08 | 2014-04-08 | |
US201562119520P | 2015-02-23 | 2015-02-23 | |
PCT/IB2015/052493 WO2015155673A1 (en) | 2014-04-08 | 2015-04-07 | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir |
Publications (1)
Publication Number | Publication Date |
---|---|
IL248095A0 true IL248095A0 (en) | 2016-11-30 |
Family
ID=53264692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL248095A IL248095A0 (en) | 2014-04-08 | 2016-09-27 | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3129009A1 (en) |
AU (1) | AU2015245217A1 (en) |
CA (1) | CA2942877A1 (en) |
IL (1) | IL248095A0 (en) |
TW (1) | TW201622731A (en) |
WO (1) | WO2015155673A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6433085B2 (en) | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル, インコーポレイテッド | 2-acetylnaphtho [2,3-b] furan-4,9-dione for use in the treatment of cancer |
KR101820084B1 (en) * | 2016-03-31 | 2018-01-18 | 한미약품 주식회사 | Solid formulation for oral administration containing tenofovir disoproxil and a process for the preparation thereof |
KR101777564B1 (en) | 2016-05-30 | 2017-09-12 | 영남대학교 산학협력단 | Tablet composition comprising tenofovir disoproxil free base and preparation method thereof |
US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
JP2020512377A (en) * | 2017-03-30 | 2020-04-23 | ボストン バイオメディカル, インコーポレイテッド | Composition for treating and / or preventing cancer |
CN108727401A (en) * | 2017-04-20 | 2018-11-02 | 盐城迪赛诺制药有限公司 | Darunavir novel crystal forms and its preparation method and application |
WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
CN111407736A (en) * | 2020-03-30 | 2020-07-14 | 苏州弘森药业股份有限公司 | Preparation process of tenofovir disoproxil fumarate tablets |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
KR100296463B1 (en) | 1992-08-25 | 2001-10-24 | 죤 에이치. 뷰센 | Hydroxyethylaminosulfonamide Useful as Retroviral Protease Inhibitor |
MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
MY121765A (en) | 1998-07-20 | 2006-02-28 | Abbott Lab | Polymorph of ritonavir |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
AP2089A (en) | 2003-01-14 | 2010-01-11 | Gilead Sciences Inc | Compositions and methods for combination antiviraltherapy |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
MXPA06014930A (en) * | 2004-07-08 | 2007-02-28 | Tibotec Pharm Ltd | Combination of anti-hiv reverse transcriptase and protease inhibitors. |
TWI471145B (en) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
EP2160394A1 (en) * | 2007-05-22 | 2010-03-10 | Ultimorphix Technologies B.v. | Tenofovir disoproxil hemi-fumaric acid co-crystal |
PA8809601A1 (en) | 2007-12-24 | 2009-07-23 | Cipla Ltd | ANTI-RETROVIRAL COMBINATION |
EP2365798A2 (en) * | 2008-11-21 | 2011-09-21 | Ultimorphix Technologies B.v. | Wet granulation of tenofovir, emtricitabine and efavirenz |
EP2332544A1 (en) | 2009-11-20 | 2011-06-15 | Assistance Publique, Hopitaux De Paris | New pharmaceutical composition suitable for treating persons affected by human immunodeficiency virus (HIV) |
EP2332532A1 (en) * | 2009-11-20 | 2011-06-15 | Assistance Publique, Hopitaux De Paris | New multi-therapy administration patterns suitable for treating persons affected by human immunodeficiency virus (HIV) |
CN103841962B (en) | 2011-07-07 | 2016-08-17 | 爱尔兰詹森科学公司 | Darunavir preparation |
WO2013057469A1 (en) | 2011-10-20 | 2013-04-25 | Cipla Limited | Pharmaceutical antiretroviral compositions |
GB201119032D0 (en) * | 2011-11-03 | 2011-12-14 | Isis Innovation | Multisomes: encapsulated droplet networks |
EA026138B1 (en) * | 2012-02-03 | 2017-03-31 | Джилид Сайэнс, Инк. | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
US20140163096A1 (en) * | 2012-12-07 | 2014-06-12 | Pam Golden | Methods and compositions for treating hiv-associated diarrhea |
IN2013MU01749A (en) | 2013-05-15 | 2015-06-26 | Cipla Ltd | |
MX2016002560A (en) * | 2013-08-29 | 2016-10-26 | Teva Pharma | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir. |
-
2015
- 2015-04-07 WO PCT/IB2015/052493 patent/WO2015155673A1/en active Application Filing
- 2015-04-07 CA CA2942877A patent/CA2942877A1/en not_active Abandoned
- 2015-04-07 TW TW104111149A patent/TW201622731A/en unknown
- 2015-04-07 EP EP15724361.9A patent/EP3129009A1/en not_active Withdrawn
- 2015-04-07 AU AU2015245217A patent/AU2015245217A1/en not_active Abandoned
-
2016
- 2016-09-27 IL IL248095A patent/IL248095A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2942877A1 (en) | 2015-10-15 |
EP3129009A1 (en) | 2017-02-15 |
TW201622731A (en) | 2016-07-01 |
AU2015245217A1 (en) | 2016-10-13 |
WO2015155673A1 (en) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1249103B (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
HK1248547A1 (en) | Pharmaceutical formulations comprising tenofovir and emtricitabine | |
EP3302442A4 (en) | Dosage forms and use thereof | |
IL248095A0 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir | |
IL252397A0 (en) | Pharmaceutical composition, preparation and uses thereof | |
IL290114A (en) | Pharmaceutical composition, preparation and uses thereof | |
HK1220390A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
PL3229843T3 (en) | Pharmaceutical composition, preparation and uses thereof | |
HK1223630A1 (en) | Dosage and administration anti-egfr therapeutics -egfr | |
HRP20181406T1 (en) | Pharmaceutical dosage forms | |
HRP20182167T1 (en) | Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof | |
PT3023093T (en) | Medicinal preparation based on diosmectite |